Shahrzad Ezzatpour

This paper develops a bireporter recombinant SARS-CoV-2 Omicron BA.5 strain for tracking viral infections and testing antivirals and neutralizing antibodies in vitro and in vivo.

This paper develops a recombinant SARS-CoV-2 virus expressing reporter genes to track viral infection in wild-type mice, showing it can be used for vaccine and antiviral research without needing transgenic models.

This paper develops a cell-free method to produce Nipah virus membrane proteins in liposomes for vaccine design, showing improved protein incorporation and enhanced immune responses in mice.

This study shows that a deletion in the NSP1 protein of SARS-CoV-2 variants reduces virulence by impairing host translation shutoff, suggesting NSP1 as a target for antiviral strategies.

This study identifies the L260F mutation in NSP6 as enhancing RNA replication and pathogenesis in recent SARS-CoV-2 variants, independent of Spike function.

The paper uses CRISPR screens to identify mucins as key host factors that restrict SARS-CoV-2 infection in human lung cells.